These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 18645692)
1. Postmenopausal hormone therapy and the risk of venous thromboembolism. Rachoń D; Teede H Climacteric; 2008 Aug; 11(4):273-9. PubMed ID: 18645692 [TBL] [Abstract][Full Text] [Related]
2. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Høibraaten E; Qvigstad E; Arnesen H; Larsen S; Wickstrøm E; Sandset PM Thromb Haemost; 2000 Dec; 84(6):961-7. PubMed ID: 11154141 [TBL] [Abstract][Full Text] [Related]
3. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results. Kuhl H; Stevenson J Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155 [TBL] [Abstract][Full Text] [Related]
4. Considerations in the choice of oral vs. transdermal hormone therapy: a review. Minkin MJ J Reprod Med; 2004 Apr; 49(4):311-20. PubMed ID: 15134159 [TBL] [Abstract][Full Text] [Related]
5. [After the early termination of the Women's Health Initiative study. New American recommendations for postmenopausal hormone therapy]. Stjernquist M; Lakartidningen; 2003 May; 100(20):1790-7. PubMed ID: 12806859 [TBL] [Abstract][Full Text] [Related]
6. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Canonico M; Plu-Bureau G; Scarabin PY Maturitas; 2011 Dec; 70(4):354-60. PubMed ID: 22024394 [TBL] [Abstract][Full Text] [Related]
7. How do you decide on hormone replacement therapy in women with risk of venous thromboembolism? Lekovic D; Miljic P; Dmitrovic A; Thachil J Blood Rev; 2017 May; 31(3):151-157. PubMed ID: 27998619 [TBL] [Abstract][Full Text] [Related]
8. Combined hormonal contraception and venous thromboembolism. Martínez F; Avecilla A Eur J Contracept Reprod Health Care; 2007 Jun; 12(2):97-106. PubMed ID: 17559006 [TBL] [Abstract][Full Text] [Related]
17. Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study. Bouaziz E; Canonico M; Verstuyft C; Carcaillon L; Martin F; Scarabin PY; Guiochon-Mantel A; Maturitas; 2009 Oct; 64(2):136-8. PubMed ID: 19782484 [TBL] [Abstract][Full Text] [Related]
18. Prevention and treatment of hormone-associated venous thromboembolism: a patient management approach. Ueng J; Douketis JD Hematol Oncol Clin North Am; 2010 Aug; 24(4):683-94, vii-viii. PubMed ID: 20659653 [TBL] [Abstract][Full Text] [Related]
19. The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy? Shulman LP J Fam Pract; 2004 Jul; Suppl():S13-7. PubMed ID: 15251108 [No Abstract] [Full Text] [Related]
20. [Hormone replacement Up-to-date. Menopause in women and hormone replacement therapy (HRT). Indications for HRT in postmenopausal women]. Ohta H Clin Calcium; 2007 Sep; 17(9):1315-24. PubMed ID: 17767019 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]